ReviewTranslational lung cancer research2026
The resistance landscape of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer: molecular mechanisms and novel therapeutic strategies.
Review in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predictive modeling of peripheral blood EGFR positivity in patients with advanced primary non-small cell lung cancer.Translational lung cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains the leading cause of global cancer-related mortality, with non-small cell lung cancer (NSCLC) constituting the predominant histological subtype. The discovery of epidermal growth factor receptor (EGFR) as a driver oncogene and elucidation of its mechanism of action through three canonical signaling pathways have driven the evolution of tyrosine kinase inhibitors (TKIs) from first to third generation. Following this breakthrough, EGFR-TKIs have revolutionized the treatment landscape for advanced EGFR-mutant NSCLC, significantly improving patient outcomes compared to conventional chemotherapy. However, the development of acquired resistance to EGFR-TKIs presents a major clinical challenge, ultimately limiting their long-term efficacy. Understanding this evolutionary trajectory and the architectural logic of the underlying signaling network lays the foundation for deciphering resistance mechanisms and designing next-generation therapeutic strategies. This comprehensive review systematically examines the molecular mechanisms underlying both intrinsic and acquired resistance to EGFR-TKIs, with a particular focus on third-generation agents like osimertinib. Key resistance mechanisms encompass on-target EGFR modifications (including tertiary C797S mutations and T790M loss), activation of bypass signaling pathways (such as MET, HER2, and AXL amplification), downstream pathway alterations (involving KRAS/BRAF and PI3K/AKT/mTOR cascades), and histologic transformations [including small cell lung cancer (SCLC) transformation and epithelial-mesenchymal transition (EMT)]. The review further explores current and emerging strategies to overcome these resistance mechanisms, including the development of fourth-generation TKIs, rational combination therapies targeting parallel pathways, and biomarker-guided treatment approaches. Understanding the complex landscape of EGFR-TKI resistance is paramount for developing novel therapeutic strategies and optimizing clinical outcomes for patients with advanced EGFR-mutant NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.